Compare PCYO & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCYO | TTRX |
|---|---|---|
| Founded | 1976 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.5M | 285.1M |
| IPO Year | 1995 | 2025 |
| Metric | PCYO | TTRX |
|---|---|---|
| Price | $11.43 | $9.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 79.8K | 46.1K |
| Earning Date | 04-08-2026 | 05-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.50 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $1,227,787.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $31.75 | ★ N/A |
| Revenue Growth | ★ 171.54 | N/A |
| 52 Week Low | $9.71 | $2.57 |
| 52 Week High | $12.44 | $11.69 |
| Indicator | PCYO | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.78 | 58.30 |
| Support Level | $10.51 | $2.81 |
| Resistance Level | $11.65 | $10.72 |
| Average True Range (ATR) | 0.30 | 0.62 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 48.95 | 55.41 |
Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in three business segments namely Water and wastewater resource development, Land development, and the Single-Family Rental Segment. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.